REPUBLIC OF LEBANON MINISTRY OF PUBLIC HEALTH Lebanon Clinical Trials Registry

Patiromer for treatment of hyperkalaemia in children from birth to <6 years of age

10/08/2025 22:50:17

Main Information	
Primary registry identifying number	Protocol number
LBCTR2023055223	RLY5016-208p
MOH registration number	
Study registered at the country of origin	Study registered at the country of origin: Specify
Yes	
Type of registration	Type of registration: Justify
Prospective	N/A
Date of registration in national regulatory agency 14/12/2022	
Primary sponsor	Primary sponsor: Country of origin
Vifor Pharma, Inc.	USA
Date of registration in primary registry	Date of registration in national regulatory agency
13/06/2023	14/12/2022
Public title	Acronym
Patiromer for treatment of hyperkalaemia in children from birth to <6 years of age	
Scientific title	Acronym
A 2-Part, Open-Label, Phase 2, Multiple Dose Study to Evaluate the Pharmacodynamic Effects, Safety, and Tolerability of Patiromer in Children under 6 Years of Age with Hyperkalaemia (EMERALD 2)	
Brief summary of the study: English	
This is a 2-part, multicentre, open-label, Phase 2, multiple dose, 2- age cohort (0 to <2 and 2 to <6 years of age) study, consisting of a 4-week pharmacodynamic (PD)/dose-ranging period followed by an optional 52-week safety-extension period to assess change in potassium levels from baseline to Day 28 following administration of different doses of patiromer administered in children 0 to <6 years of age with hyperkalaemia and To assess the safety and tolerability of patiromer in children 0 to <6 years of age with hyperkalaemia.The maximum study duration for a participant will be up to 58 weeks, including an up to 2 weeks screening period, a 4- week PD/dose-ranging period (Part 1), and a 52-week optional safety-extension period (Part 2).The study will include 2 cohorts: Cohort A (2 to <6 years of age) and Cohort B (0 to <2 years of age).	
Brief summary of the study: Arabic	
جر عة متعددة ، فنة عمرية 2هذه در اسة مكونة من جزئين ، متعددة المراكز ، مفتوحة التسمية ، المرحلة . أمان اختيارية مدتها / (PD) أسابيع من الديناميكيات الدوائية4 سنوات من العمر) ، وتتألف من 6من مير المعطى للأطفال من سن 28أسبو عاً لتقييم التغيير في مستويات البوتاسيوم من خط الأساس إلى البوم ن 0 سنوات مع فرط بوتاسيوم الدم ولتقييم السلامة وتحمل البيرومير لدى الأطفال من سن 6إلى أقل من ، بما في ذلك فترة فحص تصل إلى أسبو عين ، و 188لدم ، وستصل مدة الدراسة القصوى الماسة الي جموعتين: الفوج أ (من 2 أسبوعيّا (الجزء 52الجرعة (الجزء الأول) ، وفترة تمديد أمول اختيارية مدتها	إلى أقل و 2 إلى أقل من 0 (من 2 ، 25فترة الجرعة منبوعة بغترة تمديد 0 بعد إعطاء جرعات مختلفة من بائيروم سنوات مع فرط بوتاسيوم6 إلى أقل مر فترة نطاق / PD أسابيع4 أسبوعًا 6 إلى أقل من 2). ستشمل الدراسة مج

. (إلى أقل من سنُتين من العمر (سنوات من العمر) والفوج ب (من

 \sim



REPUBLIC OF LEBANON Lebanon Clinical Trials Registry

Health conditions/problem studied: Specify

Hyperkalaemia

Interventions: Specify

The study will include 2 parts: 1) a 4-week PD/dose-ranging period in an interventional clinical trial setting, followed by 2) an optional 52-week safety-extension period. In the optional safety-extension period, the frequency and procedures of visits will adhere to the standard of care for paediatric subjects of the specific study site; however, at least every 3 months. Potassium values, patiromer dosing and compliance, and adverse events (AEs) will be reported.

During this study, potassium values can be measured as serum, plasma, whole blood, or capillary blood potassium. However, any of the above methods need to be kept constant throughout the study, from screening visit to end of study.

Key inclusion and exclusion criteria: Inclusion criteria

1. Paediatric subjects (<6 years of age) with hyperkalaemia at screening.

2. Subject's age should not reach 6 years during the 28 days of the PD/ dose-ranging period.

3. Subject is able to receive regular external feeding and medication, including via tubes, e.g., percutaneous endoscopic gastrostomy (PEG). 4. At screening/baseline, 2 potassium values need to be above the age-appropriate upper limit of normal (ULN) of the local laboratory.

However, the average of the 2 potassium values from 2 separate sample collections (1 sample from screening/baseline and 1 sample not older than 30 days) needs to be above the age-appropriate ULN of the local laboratory plus 0.5 mEq/l (equivalent to 0.5 mmol/l).

5. In the opinion of the Investigator, the subject is expected to require treatment for hyperkalaemia for at least 28 days upon enrolment in the studv.

6. If taking any renin-angiotensin aldosterone system inhibitors (RAASi), beta blockers, fludrocortisone, or diuretic medications, must be on a stable dose for at least 14 days prior to screening.

7. Parent(s) or legally acceptable representative(s) has provided the appropriate written informed consent, in accordance with local regulations. The assent of the child should also be obtained when appropriate or if requested by the Institutional Review Board (IRB)/Ethics Committee (EC)/Independent Ethics Committee (IEC). The written informed consent must be provided before any study-specific procedures are performed including screening procedures.

8. Parent(s) or legally authorised representative(s) or another appropriate person delegated by the legally authorised representatives must be available to help the study-site personnel ensure follow-up; accompany the participant to the study site on each assessment day according to the Schedule of Events (Table 1, Table 2) (e.g., able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures); accurately and reliably dispense investigational product as directed.

Key inclusion and exclusion criteria: Gender	Key inclusion and exclusion criteria: Specify gender
Both	
Key inclusion and exclusion criteria: Age minimum	Key inclusion and exclusion criteria: Age maximum
0	5

Key inclusion and exclusion criteria: Exclusion criteria

1. Preterm birth infants with <37 weeks of gestation cannot be included in Cohort B.

2. Participants who due to their general condition, e.g., anaemia or low body weight are not suitable to have blood volume withdrawn as specified in the Schedule of Events (Table 1, Table 2).

3. Subjects with pseudo-hyperkalaemia due to haemolysis or to abnormally high numbers of platelets (above ULN), leukocytes (above ULN), or erythrocytes (above ULN) at screening based on results obtained from the local laboratory.

4. Any subject with evidence of potential potassium-related 12-lead electrocardiogram (ECG) changes (i.e., changes consistent with hyper- or hypokalaemia) at screening.

5. Any subject with serum magnesium <1.4 mg/dl at screening/baseline.

6. Any of the following renal conditions: maintenance haemodialysis or peritoneal dialysis, renal artery stenosis, and acute kidney injury (defined by 2012 Kidney Disease Improving Global Outcomes) or a history of acute renal insufficiency in the past 3 months. Note: CKD is not excluded.

7. A history of or current diagnosis of a severe gastrointestinal (GI) diagnosis or surgery that could affect GI transit of the drug (delayed gastric emptying), such as a severe swallowing disorder, severe gastroesophageal reflux, uncorrected pyloric stenosis, intussusception, any other intestinal obstruction (e.g., Hirschsprung disease, chronic intestinal pseudo-obstruction, clinically significant postsurgical abdominal adhesions) or any gut-shortening surgical procedure prior to screening. Pre-gastric above-mentioned pathologies may be disregarded in case of existence of a PEG tube, as the PEG tube will serve for nutrition and investigational product administration.

8. Liver enzymes (alanine aminotransferase, aspartate aminotransferase) more than 3 times the ULN at screening, based on the local laboratory, as well as subject's respective age.

9. Active cancer, currently on cancer treatment, or history of cancer in the past 2 years (except for non-melanoma skin cancer).

10. Recipient of any organ transplant requiring treatment with immunosuppressive therapy or scheduled for kidney transplant procedure during the first 28 days after Day 1.

11. History of sudden infant death in a sibling.

12. Has severe hypoxaemia, respiratory acidosis, asphyxia, or hypotension 3 months before screening based on assessment of the Investigator.

13. Subjects treated with sodium polystyrene sulphonate, calcium polystyrene sulphonate, or sodium zirconium cyclosilicate within the last 48 hours prior to fulfilling the baseline potassium assessments requested in Inclusion Criterion 4.

14. Use of the following medications if doses have not been stable for at least 14 days prior to screening or if doses are anticipated to change during the 4-week PD/dose-ranging period: digoxin, bronchodilators, theophylline, heparins (including low molecular heparins), tacrolimus, mycophenolate mofetil, cyclosporine, trimethoprim, or cotrimoxazole.

15. Use of any investigational product for an unapproved indication within 30 days prior to screening or within 5 half-lives, whichever is longer. 16. Known hypersensitivity to patiromer or its components.

17. In the opinion of the Investigator, parent(s) or legal representative(s) inability to comply with the protocol.

MINISTRY OF PUBLIC HEALTH

REPUBLIC OF LEBANON Lebanon Clinical Trials Registry

18. In the opinion of the Investigator, any medical condition, uncontrolled systemic disease, or serious intercurrent illness that would significantly decrease study compliance or jeopardise the safety of the subject or potentially affect the quality of the data such as: hyperkalaemia at screening that requires emergency intervention; cardiovascular event or intervention within 3 months prior to screening; a haemodynamically unstable arrhythmia; hospitalisation for heart failure within the past 3 months; poorly controlled blood pressure; poorly controlled diabetes mellitus or frequent need for adjustment in insulin prescription or recent hospitalisation for treatment of hyper or hypoglycaemia.

19. If the child is being breastfed:

a) There is suspicion of current alcohol or substance misuse/abuse in breastfeeding mother

b) The breastfeeding mother is taking potassium supplements.

Type of study			
Interventional			
Type of intervention	Type of intervention: Spe	cify type	
Pharmaceutical	N/A		
Trial scope	Trial scope: Specify scop	e	
Other			
Study design: Allocation	Study design: Masking		
Non-randomized controlled trial	Open (masking not used)		
Study design: Control	Study phase		
N/A	2		
Study design: Purpose	Study design: Specify pu	rpose	
Other	Pharmacodynamic, Efficacy	v, Safety, Dose response	
Study design: Assignment	Study design: Specify ass	signment	
Other	cohort design		
IMP has market authorization	IMP has market authoriza	tion: Specify	
Yes, Lebanon and Worldwide	USA, EU, Norway, Iceland, Australia, Eurasian Econor	Lichtenstein, Switzerland and nic Union (EAEU; Russia)	
Name of IMP	Year of authorization	Month of authorization	
Patiromer	2015	10	
Type of IMP			
Others			
Pharmaceutical class			
Potassium binder			
Therapeutic indication			
treatment of hyperkalaemia in Pediatric population			
Therapeutic benefit			
This study will assess safety and dosing in this population an treatment for hyperkalaemic paediatric subjects.	d represents at the same time a potential		
Study model	Study model: Explain mod	del	
N/A	N/A		
Study model: Specify model			
N/A			
Time perspective	Time perspective: Explair	time perspective	

REPUBLIC OF LEBANON Lebanon Clinical Trials Registry

N/A	N/A
Time perspective: Specify perspective N/A	
Target follow-up duration	Target follow-up duration: Unit
Number of groups/cohorts	
Biospecimen retention None retained	Biospecimen description NA
Target sample size	Actual enrollment target size
Date of first enrollment: Type Anticipated	Date of first enrollment: Date 17/04/2023
Date of study closure: Type Anticipated	Date of study closure: Date 30/04/2026
Recruitment status Other	Recruitment status: Specify Not Initiated
Date of completion	
IPD sharing statement plan Yes	IPD sharing statement description The sponsor assures that the key design elements of this protocol will be posted in a publicly accessible database such as ClinicalTrials.gov. The clinical study report will be submitted to the regulatory authorities in Lebanon within one year of the end of the study (worldwide). The detailed obligations regarding the publication of any data, material results, or other information generated or created in relation to the study shall be set out in the
Additional data URL	agreement between each investigator and the sponsor.
Admin comments	
Trial status Approved	



Lebanon Clinical Trials Registry

Secondary Identifying Numbers

No Numbers

Sources of Monetary or Material Support

No Sources

Secondary Sponsors

No Sponsors

Contact for Public/Scientific Queries						
Contact type	Contact full name	Address	Country	Telephone	Email	Affiliation
Public	Aziz Zoghbi	MCT-CRO,Berytech Technology and Health,5th Floor Damascus Road,Beirut,Lebanon	Lebanon	009611612 500	zog_az@mctcro. com	Regional Manager
Scientific	Chebl Mourani	Hotel Dieu de France, Alfred Naccache Avenue, Achrafieh, Beirut, Lebanon	Lebanon	009613185 632	cheblmourani@g mail.com	Principal Investigato r
Scientific	Katia El Taoum	AUBMC	Lebanon	+9618822 363	ke27@aub.edu.l b	Principal Investigato r

Centers/Hospitals Involved in the Study			
Center/Hospital name	Name of principles investigator	Principles investigator speciality	Ethical approval
Hotel dieu de france	Chebl Mourani	Pediatric nephrology	Approved
American University of Beirut Medical Center	Katia El Taoum	Pediatric	Pending

Ethics Review				
Ethics approval obtained	Approval date	Contact name	Contact email	Contact phone
Hotel Dieu de France	31/01/2023	Nancy Alam	nancy.alam@usj.edu.lb	+961 1 421 000 ext 2335



Countries of Recruitment

Name

United States of America

Health Conditions or Problems Studied			
Condition	Code	Keyword	
hyperkalaemia	Hyperkalaemia (E87.5)	hyperkalaemia	

Interventions			
Intervention	Description	Keyword	
Patiromer for Cohort A (2 to <6 years of age)	The patiromer starting dose is based on Body Weight (Based on Outcomes and DSMB Recommendation).Titration during the study will depend on the potassium response of the subject.	Patiromer	
Patiromer for Cohort B (0 to <2 years of age)	To ensure safety in Cohort B, dosing will begin with Cohort A (2 to <6 years of age). After 3 subjects from Cohort A have completed 4 weeks of treatment, the Data Safety and Monitoring Board (DSMB) will evaluate safety in these 3 subjects. If the safety profile is acceptable, enrolment will then proceed in Cohort B (0 to <2 years of age). The patiromer starting dose in Cohort B is based on body weight and DSMB recommendations, and it will be adapted during the study depending on the potassium response of the subject.	Patiromer	

Primary Outcomes			
Name	Time Points	Measure	
change in potassium levels	from baseline to Day 28	blood potassium	



Lebanon Clinical Trials Registry

Key Secondary Outcomes		
Name	Time Points	Measure
change in potassium levels	from baseline to Day 3, Day 7, and Day 14 and end of the study Part 1 and during the optional safety- extension period.	blood potassium
treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)	Part 1: Day 1 up to end of treatment (Day 28 ±3 Days); Part 2: Day 1 up to follow-up visit (Up to 54 weeks)]	ΝΑ
vital signs, 12-lead ECG, and clinical safety laboratory evaluations	From baseline to Day 3, Day 7, Day 14, Day 28 and during Part 2: up to 52 weeks	Change in resting heart rate (beats per minute) in systolic blood pressure (mmHg) in diastolic blood pressure (mmHg) in body temperature (Celsius) Normal and abnormal 12-lead electrocardiogram (ECG) findings
occurrence of blood potassium	From baseline to Day 3, Day 7, Day 14, Day 28 and during Part 2: up to 52 weeks	blood potassium
Occurrence of blood magnesium	From baseline to Day 3, Day 7, Day 14, Day 28 and during Part 2: up to 52 weeks	blood magnesium
Occurrence of serum calcium, phosphate, fluoride, creatinine, bicarbonate, and blood urea nitrogen levels	From baseline to Day 3, Day 7, Day 14, Day 28 and during Part 2: up to 52 weeks	blood test



Trial Results Summary results Study results globally Date of posting of results summaries Date of first journal publication of results Results URL link Baseline characteristics Participant flow Adverse events Outcome measures URL to protocol files